EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer

Zhijing Shi iD, Yiman Li, Huijie Hou, Zhitao Wang, Hui Guo, Yang Yu, Yan Song, Zhe Chen

Journal of Clinical Laboratory Analysis · 2025

DOI: 10.1002/jcla.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2025. Verfasst von Zhijing Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Tianjin Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advancements in non‐small cell lung cancer (NSCLC) therapies have improved outcomes, but challenges like low immune response, drug resistance, and side effects persist. ACT001, a novel small‐molecule inhibitor, shows promise in addressing these issues.

Methods

We evaluated ACT001's anti‐tumor and immunomodulatory effects in NSCLC. In vitro, its impact on proliferation, migration, invasion, and cell cycle arrest was assessed. In vivo, its effect on tumor growth in C57BL/6 mice was studied. Pull‐down assays and mass spectrometry identified ACT001's interaction with STAT1/STAT3 and its regulation of PD‐L1 expression.

Results

ACT001 inhibited NSCLC cell proliferation, migration, and invasion, induced cell cycle arrest, and suppressed tumor growth in vivo. It enhanced granzyme B release in CD3 + T cells, promoting NSCLC cell apoptosis. Mechanistically, ACT001 bound to STAT1/STAT3, suppressing their phosphorylation and reducing PD‐L1 expression.

Conclusion

ACT001 exhibits antitumoral and immunomodulatory potential by targeting STAT1/STAT3 and regulating PD‐L1, offering a promising therapeutic approach for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsAnimalsHumansSTAT1 Transcription FactorSTAT3 Transcription FactorMiceCell Line, TumorCell ProliferationMice, Inbred C57BLB7-H1 AntigenCell MovementApoptosisDisease Progression

Stichwörter der Autor:innen

ACT001PD‐L1STAT1STAT3non‐small cell lung cancer

Substanzen

STAT1 Transcription FactorSTAT3 Transcription FactorB7-H1 AntigenSTAT1 protein, humanAntineoplastic AgentsSTAT3 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin, China.
  • Health Management Centre, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Geriatrics, Tianjin Geriatrics Institute, Tianjin Medical University General Hospital, Tianjin, China.

ORCID-Profile: Zhijing Shi

Förderung

  • Science and Technology Project of Tianjin Municipal Health Commission

Zitieren

APA

Shi, Z., Li, Y., Hou, H., Wang, Z., Guo, H., Yu, Y., Song, Y., & Chen, Z. (2025). ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70066

Vancouver

Shi Z, Li Y, Hou H, Wang Z, Guo H, Yu Y, et al. ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer. Journal of Clinical Laboratory Analysis. 2025. doi:10.1002/jcla.70066

BibTeX
@article{Shi2025,
  author = {Shi, Zhijing and Li, Yiman and Hou, Huijie and Wang, Zhitao and Guo, Hui and Yu, Yang and Song, Yan and Chen, Zhe},
  title = {ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2025},
  doi = {10.1002/jcla.70066}
}
Kostenlos starten →